Skip to main content
editorial
. 2011 Mar 10;2(3):150–157. doi: 10.5306/wjco.v2.i3.150

Table 1.

Selected clinical trials on targeted agents for advanced/metastatic thyroid carcinomas

Trial Phase Setting Patients Targeted agent DCR
Cooney et al[38] II Advanced pretreated disease 18 with ATC CA4P alone 33%
Cohen et al[46] II Advanced pretreated disease 60 (2 with ATC) Axitinib alone 71%
Ha et al[53] II Advanced pretreated disease 11 with ATC Imatinib alone 75%
Nagaiah et al[54] II Advanced pretreated disease 16 with ATC Sorafenib alone 40%

ATC: Anaplastic thyroid carcinoma; CA4P: Combretastatin A4; DCR: Disease control rate (complete responses + partial responses + stable disease).